Safety and tumor specificity of cetuximab-IRDye800 for surgical navigation in head and neck cancer

Clinical Cancer Research

Volumn 21, Issue 16, 2015, Pages 3658-3666

  Rosenthal, Eben L ^a   Warram, Jason M ^a   De Boer, Esther ^a,b   Chung, Thomas K ^a   Korb, Melissa L ^c   Brandwein Gensler, Margie ^d   Strong, Theresa V ^e   Schmalbach, Cecelia E ^a   Morlandt, Anthony B ^f   Agarwal, Garima ^a   Hartman, Yolanda E ^a   Carroll, William R ^a   Richman, Joshua S ^c   Clemons, Lisa K ^a   Nabell, Lisle M ^e   Zinn, Kurt R ^g  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c University of Alabama at Birmingham   (United States)

^d University of Alabama at Birmingham   (United States)

^e Heerskink School of Medicine   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^g University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; DYE; INFRARED DYE 800; UNCLASSIFIED DRUG; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUORESCENT DYE; INDOLE DERIVATIVE; IRDYE800; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER PAIN; CANCER SURGERY; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DIZZINESS; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG SPECIFICITY; FEMALE; FLUORESCENCE IMAGING; GLOSSECTOMY; HEAD AND NECK CANCER; HEMODYNAMICS; HUMAN; HUMAN TISSUE; HYPOMAGNESEMIA; HYPOTENSION; IMMUNOREACTIVITY; KARNOFSKY PERFORMANCE STATUS; MALE; MIDDLE AGED; NEAR INFRARED IMAGING SYSTEM; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; QT PROLONGATION; QUANTITATIVE ANALYSIS; SINUS BRADYCARDIA; TUMOR DIFFERENTIATION; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIAL; DIAGNOSTIC IMAGING; HEAD AND NECK NEOPLASMS; PATHOLOGY; RADIOGRAPHY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; CARCINOMA, SQUAMOUS CELL; CETUXIMAB; FEMALE; FLUORESCENT DYES; HEAD AND NECK NEOPLASMS; HUMANS; INDOLES; MALE; MIDDLE AGED; OPTICAL IMAGING; RADIOGRAPHY; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84942847480     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-3284     Document Type: Article

References (25)

1. Arbes SJ Jr., Olshan AF, Caplan DJ, Schoenbach VJ, Slade GD, Symons MJ. Factors contributing to the poorer survival of black Americans diagnosed with oral cancer (United States). Cancer Causes Control 1999;10:513-23.
2. Woolgar JA, Triantafyllou A. A histopathological appraisal of surgical margins in oral and oropharyngeal cancer resection specimens. Oral Oncol 2005;41:1034-43.
3. McMahon J, O'Brien CJ, Pathak I, Hamill R, McNeil E, Hammersley N, et al. Influence of condition of surgicalmargins on local recurrence and diseasespecific survival in oral and oropharyngeal cancer. Br JOralMaxillofac Surg 2003;41:224-31.
4. Hinni ML, Ferlito A, Brandwein-Gensler MS, Takes RP, Silver CE, Westra WH, et al. Surgical margins in head and neck cancer: a contemporary review. Head Neck 2013;35:1362-70.
5. Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 2006;7:392-401.
6. StummerW, Novotny A, SteppH, Goetz C, Bise K, Reulen HJ. Fluorescenceguided resection of glioblastoma multiforme by using 5-aminolevulinic acid-induced porphyrins: a prospective study in 52 consecutive patients. J Neurosurg 2000;93:1003-13.
7. StummerW, Reulen HJ, Novotny A, SteppH, Tonn JC. Fluorescence-guided resections of malignant gliomas-an overview. Acta Neurochir Suppl 2003;88:9-12.
8. Millesi M, Kiesel B, Woehrer A, Hainfellner JA, Novak K, Martinez-Moreno M, et al. Analysis of 5-aminolevulinic acid-induced fluorescence in 55 different spinal tumors. Neurosurg Focus 2014;36:E11.
9. Taruttis A, Ntziachristos V. Translational optical imaging. AJR Am J Roentgenol 2012;199:263-71.
10. Thurber GM, Figueiredo JL, Weissleder R. Multicolor fluorescent intravital live microscopy (FILM) for surgical tumor resection in a mouse xenograft model. PLoS One 2009;4:e8053.
11. Hall MA, Pinkston KL, Wilganowski N, Robinson H, Ghosh P, Azhdarinia A, et al. Comparison of mAbs targeting epithelial cell adhesion molecule for the detection of prostate cancer lymph node metastases with multimodal contrast agents: quantitative small-animal PET/CT and NIRF. J Nucl Med 2012;53:1427-37.
12. Mitsunaga M, Tajiri H, Choyke PL, Kobayashi H. Monoclonal antibodyfluorescent probe conjugates for in vivo target-specific cancer imaging: toward clinical translation. Ther Deliv 2013;4:523-5.
13. Heath CH, Deep NL, Sweeny L, Zinn KR, Rosenthal EL. Use of panitumumab-IRDye800 to image microscopic head and neck cancer in an orthotopic surgical model. Ann Surg Oncol 2012;19:3879-87.
14. Day KE, Beck LN, Deep NL, Kovar J, Zinn KR, Rosenthal EL. Fluorescently labeled therapeutic antibodies for detection of microscopic melanoma. Laryngoscope 2013;123:2681-9.
15. Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R, Hammond EH, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002;62:7350-6.
16. Rubin Grandis J, Melhem MF, Gooding WE, Day R, Holst VA, WagenerMM, et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998;90:824-32.
17. Suh Y, Amelio I, Guerrero Urbano T, Tavassoli M. Clinical update on cancer: molecular oncology of head and neck cancer. Cell Death Dis 2014;5:e1018.
18. Marshall MV, Draney D, Sevick-Muraca EM, Olive DM. Single-dose intravenous toxicity study of IRDye 800CW in Sprague-Dawley rats. Mol Imaging Biol 2010;12:583-94.
19. Zinn KR, Korb M, Samuel S, Warram JM, Dion D, Killingsworth C, et al. IND-directed safety and biodistribution study of intravenously injected cetuximab-IRDye800 in cynomolgus macaques. Mol Imaging Biol 2015;17:49-57.
20. Korb ML, Hartman YE, Kovar J, Zinn KR, Bland KI, Rosenthal EL. Use of monoclonal antibody-IRDye800CW bioconjugates in the resection of breast cancer. J Surg Res 2014;188:119-28.
21. Li Y, Rey-Dios R, Roberts DW, Valdes PA, Cohen-Gadol AA. Intraoperative fluorescence-guided resection of high-grade gliomas: a comparison of the present techniques and evolution of future strategies. World Neurosurg 2014;82:175-85.
22. Roberts DW, Valdes PA, Harris BT, Hartov A, Fan X, Ji S, et al. Glioblastoma multiforme treatment with clinical trials for surgical resection (aminolevulinic acid). Neurosurg Clin N Am 2012;23:371-7.
23. van Dam GM, Themelis G, Crane LM, Harlaar NJ, Pleijhuis RG, Kelder W, et al. Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-alpha targeting: first in-human results. Nat Med 2011;17:1315-9.
24. Thurber GM, Dane Wittrup K. A mechanistic compartmental model for total antibody uptake in tumors. J Theor Biol 2012;314:57-68.
25. Wittrup KD, Thurber GM, Schmidt MM, Rhoden JJ. Practical theoretic guidance for the design of tumor-targeting agents. Methods Enzymol 2012;503:255-68.